A 7-year-old al­liance be­tween Cel­gene and Ac­celeron is pay­ing off with more promis­ing PhI­II da­ta for lus­pa­ter­cept

Just days af­ter hit­ting its first set of marks in a crit­i­cal­ly im­por­tant Phase III study, Ac­celeron $XL­RN and its part­ners at Cel­gene $CELG say …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.